Pharmala Biotech Holdings Inc.
Pharmala Biotech Holdings Inc. (MDMA.CN) Revenue
Annual & quarterly revenue history · segment & region breakdown
MDMA.CN · revenue · updated Jun 10, 2026
Core revenue metrics
Trailing 12 monthsPharmala Biotech Holdings Inc. trailing twelve-month (TTM) revenue is $0.00B, an increase of 0.00% year-over-year from — in FY.
Revenue trend
– · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Pharmala Biotech Holdings Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Pharmala Biotech Holdings Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in USD.
Data sourced from Pharmala Biotech Holdings Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
MDMA.CN revenue · 4 questionsMDMA.CN's trailing twelve-month (TTM) revenue is $0.00B. That is an increase of 0.00% year-over-year from — in FY.
▸ Source: FMP · Pharmala Biotech Holdings Inc. SEC filings · GAAP · Pharmala Biotech Holdings Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 10, 2026